Mfg Part Number
Ab02061-10.159
Vector Labs Ab02061-10.159 Anti-Spike protein [Ty1], Human IgG1-Fc Fusion, (100 μg)
Quick Overview
The original antibody was generated by immunizing an adult male alpaca. Four rounds of immunizations were carried out during a 60 day period. For the first two rounds SARS-CoV-2 S1-sheep-FC was used as an antigen and for the last two rounds SARS-CoV-2 RBD was used as an immunogen. Selection of specific binders was done by two consecutive rounds of phage display and panning against RBD immobilized on magnetic beads.
$692.90
Order will ship within 1-3 business days
| Product Class: | Purified |
|---|---|
| Clone ID: | Ty1 |
| Synonyms: | SARS CoV 2 S glycoprotein; COVID-19 Spike protein; RBD; Receptor Binding Domain; E2 glycoprotein; E2; Human coronavirus 2 spike glycoprotein; Peplomer protein; S glycoprotein; SARS coronavirus 2 S protein; SARS coronavirus 2 Spike Protein; SARS CoV 2 Spike protein; SARS CoV 2; SARS-CoV-2 S protein; SARSCoV2; SARS-COV-2 S protein; SARS-COV-2 Spike glycoprotein; SARSCOV2 Spike protein; Severe acute respiratory syndrome 2 spike glycoprotein; Severe acute respiratory syndrome virus 2 spike glycoprotein; Spike glycoprotein; 2019-nCoV; TY-1 |
| Amount: | 100 μg |
| Application Codes Clone: | NTRL; ELISA; FC; IF; Biolayer interferometry; inhibit |
| Shipping Temperature: | Wet Ice |
| Buffer Composition: | PBS with 0.02% Proclin 300. |
| Original Format: | VHH |
| Storage Temperature: | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C. |
| Chimeric Use Statement: | This chimeric human antibody was made using the variable domain sequences of the original VHH format, for improved compatibility with existing reagents, assays and techniques. |
| Specificity Statement: | This antibody binds the receptor binding domain (RBD) of the SARS-CoV-2. Ty1 binds to an epitope on the RBD accessible in both the ‘up’ and ‘down’ conformations and that Ty1 sterically hinders RBD-ACE2 binding. |
| Application Notes: | This alpaca-derived single domain antibody targets the RBD of the SARS-CoV-2 spike glycoprotein and potently neutralizes the virus. Ty1 successfully neutralized SARS-CoV-2 pseudotyped viruses in vitro at an IC50 of 0.77 µg/ml (54 nM). The binding specificity of Ty1 to spike protein was determined by flow cytometry. Ty1 was also able to recognize the virus infected Vero E6 cells in an immunofluorescence assay. It is also reported that Ty1 recognizes and binds the viral spike protein with high specificity in its native conformation in SARS-CoV-2 infected cells. RBD bound to surface-immobilized Ty1 with high affinity in the 5-50 nM range in Biolayer Interferometry (Hanke et al., 2020). |
| Brand | Vector Labs |
|---|---|
| UNSPSC | 12161500 |